These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 32134406)

  • 1. [Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].
    Capranzano P; Francaviglia B; Capodanno D; Tamburino C
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):34S-41S. PubMed ID: 32134406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
    Verburg A; Bor WL; Küçük IT; Henriques JPS; Vink MA; Ruifrok WT; Plomp J; Heestermans TACM; Schotborgh CE; Vlaar PJ; Magro M; Rikken SAOF; van den Broek WWA; van Mieghem CAG; Cornelis K; Rosseel L; Dujardin KS; Vandeloo B; Vandendriessche T; Ferdinande B; van 't Hof AWJ; Tijssen JGP; Limbruno U; De Caterina R; Rubboli A; Angiolillo DJ; Adriaenssens T; Dewilde W; Ten Berg JM
    EuroIntervention; 2024 Jul; 20(14):e898-e904. PubMed ID: 39007830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention.
    Manzi L; Florimonte D; Forzano I; Buongiorno F; Sperandeo L; Castiello DS; Paolillo R; Giugliano G; Giacoppo D; Sciahbasi A; Cirillo P; Esposito G; Gargiulo G
    Interv Cardiol Clin; 2024 Oct; 13(4):527-541. PubMed ID: 39245552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL; Hansen CL
    Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological strategy pre- and post-percutaneous coronary intervention in patients with acute coronary syndrome on oral anticoagulation therapy].
    Franchina AG; Capodanno D
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):26S-33S. PubMed ID: 32134405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.
    Sammut MA; Conway D; Iqbal J; Krishnamurthy A; Morgan KP; Morris PD; Richardson JD; Rothman AMK; Gunn JP; Storey RF
    Expert Rev Cardiovasc Ther; 2024 Jul; 22(7):339-345. PubMed ID: 38949642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
    Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
    Verlinden NJ; Coons JC; Iasella CJ; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):546-551. PubMed ID: 28279076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short dual antiplatelet therapy: how, when and why].
    Ditali V; Carrozzi C; Leonardi S
    G Ital Cardiol (Rome); 2020 Feb; 21(2 Suppl 1):14S-25S. PubMed ID: 32134404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    Tanner R; Cronin M; Macken L; Murphy R; Maree AO; Ullah I; Cosgrave J; O'Connor S; Daly C
    J Cardiovasc Pharmacol; 2021 Apr; 77(4):501-507. PubMed ID: 33818553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    Maeng M; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2346-2355. PubMed ID: 31806216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Ather A; Laliberte B; Reed BN; Schenk A; Watson K; Devabhakthuni S; See VY
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):441-455. PubMed ID: 29915905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
    Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.